Decreased efficacy of drugs targeting the vascular endothelial growth factor pathway by the epigenetic silencing of FLT1 in renal cancer cells

[1]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[2]  M. Dawson,et al.  Cancer Epigenetics: From Mechanism to Therapy , 2012, Cell.

[3]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[4]  H. Dvorak,et al.  Concordant release of glycolysis proteins into the plasma preceding a diagnosis of ER+ breast cancer. , 2012, Cancer research.

[5]  Young Woo Park,et al.  Promoter methylation status of VEGF receptor genes: A possible epigenetic biomarker to anticipate the efficacy of intracellular-acting VEGF-targeted drugs in cancer cells , 2012, Epigenetics.

[6]  P. Bruzzi,et al.  Vatalanib in advanced colorectal cancer: two studies with identical results. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  H. Lee,et al.  Efficacy and Safety of Sunitinib on Metastatic Renal Cell Carcinoma: A Single-Institution Experience , 2010, Korean journal of urology.

[8]  H. Verheul,et al.  Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? , 2009, Angiogenesis.

[9]  Seung-Moo Noh,et al.  The expression of VEGF receptor genes is concurrently influenced by epigenetic gene silencing of the genes and VEGF activation , 2009, Epigenetics.

[10]  R. Dahiya,et al.  DNA methylation and histone modifications cause silencing of Wnt antagonist gene in human renal cell carcinoma cell lines , 2008, International journal of cancer.

[11]  A. Al-Attar,et al.  Vascular Endothelial Growth Factor Expression in Ovarian Cancer: A Model for Targeted Use of Novel Therapies? , 2008, Clinical Cancer Research.

[12]  Peter A. Jones,et al.  The Epigenomics of Cancer , 2007, Cell.

[13]  Ge Li,et al.  Anti-Flt1 Peptide, a Vascular Endothelial Growth Factor Receptor 1–Specific Hexapeptide, Inhibits Tumor Growth and Metastasis , 2005, Clinical Cancer Research.

[14]  L. Ellis,et al.  Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[16]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[17]  M Mazumdar,et al.  Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  D. Hicklin,et al.  Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy , 1998, Cancer and Metastasis Reviews.

[19]  Leonard,et al.  Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. , 1997, Cancer research.

[20]  T. Sugiyama,et al.  Frequent overexpression of vascular endothelial growth factor gene in human renal cell carcinoma. , 1994, The Tohoku journal of experimental medicine.

[21]  E. McFadden,et al.  Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.

[22]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[23]  Manjit,et al.  Neurology , 1912, NeuroImage.

[24]  I. Bièche,et al.  Overexpression of vascular endothelial growth factor 189 in breast cancer cells leads to delayed tumor uptake with dilated intratumoral vessels. , 2008, The American journal of pathology.

[25]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.